skip to Main Content

Dr. Golan on the Phase III POLO Trial in BRCA-Mutant Pancreatic Cancer

Newsfeed image, light gray text on dark gray background

Talia Golan, MD, head of Sheba Pancreatic Cancer Center, discusses the results of the phase III POLO trial, which evaluated maintenance olaparib (Lynparza) compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer. Watch here . . . 


Back To Top